Skip to content

Study · Not a test of the peptide alone · 2023

1 result

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists.

Ahmed S, Naz A, K M

Cureus17 Feb 2023Cited by 4 (Europe PMC)

PMID36945294 (opens in a new tab)PMCIDPMC10024922 (opens in a new tab)DOI10.7759/cureus.35102 (opens in a new tab)PepBankPUB-36945294
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Prader-Willi syndrome (PWS) is the most common genetic obesity syndrome. The clinical features of this condition include childhood obesity, hyperphagia, infantile hypotonia, hypogonadism, short stature, and characteristic facial features. The leading cause of morbidity and mortality in PWS is hyperphagia and resultant obesity. Here, we highlight the effectiveness of glucagon-like peptide-1 (GLP-1) agonists by reporting an interesting case of successful rapid weight loss in an adult with PWS using GLP-1 agonists - exenatide and liraglutide. To the best of our knowledge, this report presents the first clinical evidence supporting the use of GLP-1 receptor agonists in the treatment of genetic obesity syndromes; our patient lost a total of 125 lbs on GLP-1 analog and continues to lose weight.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In an adult with Prader-Willi syndrome, sequential treatment with exenatide and liraglutide was followed by a total weight loss of 125 lbs.

    In plain wordsIn one adult with Prader-Willi syndrome, weight fell by 125 lbs during treatment with two GLP-1 drugs, exenatide and liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal weight loss in Prader-Willi syndrome
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight loss
    125 lbs
    GLP-1 analog treatment

    Source sentences

    Summary
    our patient lost a total of 125 lbs on GLP-1 analog and continues to lose weight.
    1 context sentence
    Summary · context
    Here, we highlight the effectiveness of glucagon-like peptide-1 (GLP-1) agonists by reporting an interesting case of successful rapid weight loss in an adult with PWS using GLP-1 agonists - exenatide and liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.